BioNet News, Pertussis, Publication 06 Dec 2021 A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age Background: A phase 2 randomized-controlled safety and immunogenicity trial evaluating different doses of recombinant acellular pertussis vaccine containing genetically-inactivated pertussis… Supachai
BioNet News, Pertussis, Publication 14 Jul 2021 Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines It is increasingly understood that acellular pertussis vaccines are associated with rapid waning of vaccine-induced immune responses and a… Supachai
BioNet News, Pertussis, Publication 07 Nov 2020 Enhanced post-licensure safety surveillance A new generation of recombinant acellular pertussis vaccine containing genetically inactivated pertussis toxin (PTgen) was licensed as a monovalent pertussis… Supachai
BioNet News, Pertussis, Publication 01 Apr 2019 A Randomized Clinical Trial Boosting aP-primed adolescents with r-aP induced higher anti-PT and PT-neutralizing responses than cd/Tdap and increased PT-specific memory B cells. Despite… Supachai
BioNet News, Pertussis, Publication 01 Nov 2018 The Lancet : Infectious Diseases Vaccines containing formalin-inactivated whole-cell Bordetella pertussis strains were first developed in the USA in the 1930s, and manufacturing processes were… Supachai
BioNet News, Pertussis, Publication 20 Oct 2017 A genetically inactivated two-component acellular pertussis vaccine Supachai